| Literature DB >> 27177030 |
Lekshmy Srinivas1, Neetha N Vellichirammal1, Ann Mary Alex1, Chandrasekharan Nair2, Indu V Nair3, Moinak Banerjee4.
Abstract
BACKGROUND: In schizophrenia, genetic background may provide a substrate for intrinsic maldevelopment of the brain through environmental influences, by recruiting neurotrophic factors and cytokines, to trigger the changes that lead to impaired neuronal functions. Cytokines being the key regulators of immune/inflammatory reactions are also known to influence the dopaminergic, noradrenergic, and serotonergic neurotransmission. Therefore, functional polymorphisms in cytokine genes may result in imbalances in the pro- and anti-inflammatory cytokine production.Entities:
Keywords: Cytokines; Epistasis; Genetics; Polymorphism; Pro-inflammatory; Schizophrenia
Year: 2016 PMID: 27177030 PMCID: PMC4866417 DOI: 10.1186/s12974-016-0569-8
Source DB: PubMed Journal: J Neuroinflammation ISSN: 1742-2094 Impact factor: 8.322
List of cytokine candidate genes and their selected polymorphisms
| Gene | Locus | SNP | rs id | GMAF | Alleles | Genotyping method | Location | Predicted functional effect |
|---|---|---|---|---|---|---|---|---|
|
| 2q13 | −889G>A | rs1800587 | 0.2786 | G/A | TaqMan AD (C_9546481_20)a | Promoter | TFBS, splicing (ESE or ESS) |
|
| 2q13 | +3954 C>T, Phe105Phe | rs1143634 | 0.1328 | C/T | PCR-RFLP | Exon 4 | sSNP, splicing (ESE or ESS) |
| −31T>C | rs1143627 | 0.4724 | C/T | PCR-RFLP | Promoter | TFBS | ||
| −511C>T | rs16944 | 0.4906 | T/C | PCR-RFLP | Promoter | TFBS | ||
|
| 2q13 | (86)n VNTR | rs2234663 | 1/2 | PCR FLP | Intron 2 | Regulatory protein-binding sites | |
|
| 5q31.1 | −590C>T | rs2243250 | 0.4698 | C/T | PCR-RFLP | Promoter | TFBS |
| −33C>T | rs2070874 | 0.4012 | C/T | TaqMan AD (C_16176215_10)a | Promoter | TFBS | ||
|
| 7p21 | −597G>A | rs1800797 | 0.1382 | G/A | PCR-RFLP | Promoter | TFBS |
| −572G>C | rs1800796 | 0.3139 | G/C | PCR-RFLP | Promoter | TFBS | ||
| −174G>C | rs1800795 | 0.1412 | G/C | PCR-RFLP | Promoter | TFBS | ||
|
| 1q31 | −592A>C | rs1800872 | 0.4349 | T/G | PCR-RFLP | Promoter | TFBS |
| −819C>T | rs1800871 | 0.4347 | G/A | KASPar assay | Promoter | TFBS | ||
| −1082G>A | rs1800896 | 0.2722 | T/C | KASPar assay | Promoter | TFBS | ||
|
| 5q31.1 | rs31400T>C | rs31400 | 0.4581 | T/C | TaqMan AD (C_3141153_10)a | Promoter | Promoter/regulatory region |
| rs31480C>T | rs31480 | 0.2883 | C/T | TaqMan AD (C_2397270_10)a | Promoter | TFBS | ||
| rs40401C>T, Ser27Pro | rs40401 | 0.4195 | C/T | TaqMan AD (C_2397269_30)a | Exon 1 | nsSNP, benign | ||
|
| 6p21.3 | −308G>A | rs1800629 | 0.0903 | G/A | KASPar assay | Promoter | TFBS |
| −238G>A | rs361525 | 0.0609 | G/A | KASPar assay | Promoter | TFBS | ||
|
| 12q24.1 | +3232A>G | rs2069718 | 0.3832 | A/G | TaqMan AD (C_15799728_10)a | Intron 3 | – |
| +874A>T | rs2430561 | 0.2802 | A/T | KASPar assay | Intron 1 | NFKB binding site | ||
|
| 19q13.2 | +915G>C, Arg25Pro | rs1800471 | 0.0483 | G/C | KASPar assay | Exon 1 | nsSNP, benign |
| +869A>G, Leu10Pro | rs1800470 | 0.4547 | A/G | TaqMan AD (C_22272997_10)a | Exon 1 | nsSNP | ||
| −509C>T | rs1800469 | 0.368 | C/T | KASPar assay | Promoter | TFBS |
TFBS transcription factor binding site, ESE exonic splicing enhancer, ESS exonic splicing silencer, sSNP synonymous SNP, nsSNP nonsynonymous SNP, GMAF global minor allele frequency
aTaqMan allelic discrimination accession numbers
Fig. 1Overview of association of cytokine gene polymorphisms with schizophrenia. X-axis shows the polymorphisms screened, and Y-axis shows the P values for each polymorphism on a logarithmic scale
Genotype and allele frequencies of the associated pro-inflammatory cytokine genes and their functional significance score
| Polymorphism | Genotype | Patients | Controls |
| Model-based | Allele | Patients | Controls |
| FS score |
|---|---|---|---|---|---|---|---|---|---|---|
| IL1A -889G>A | GG | 102 (0.42) | 118 (0.49) | G | 313 (0.64) | 344 (0.71) | ||||
| rs1800587 | GA | 109 (0.45) | 108 (0.44) | 0.04 | 0.017a | A | 175 (0.36) | 142 (0.29) | 0.026 | 0.21 |
| AA | 33 (0.14) | 17 (0.07) | a2.1 (1.08–4) | 1.36 (1.04–1.8) | ||||||
| IL6 -597G>A | GG | 165 (0.67) | 149 (0.61) | G | 402 (0.82) | 382 (0.78) | ||||
| rs1800797 | GA | 72 (0.29) | 84 (0.34) | 0.38 | A | 90 (0.18) | 106 (0.22) | 0.18 | ||
| AA | 9 (0.04) | 11 (0.05) | ||||||||
| IL6 -572G>C | GG | 62 (0.25) | 81 (0.33) | G | 268 (0.54) | 273 (0.56) | ||||
| rs1800796 | GC | 144 (0.59) | 111 (0.45) | 0.015 | 0.003b | C | 224 (0.46) | 215 (0.44) | 0.64 | |
| CC | 40 (0.16) | 52 (0.21) | b1.7 (1.18–2.42) | |||||||
| IL6 -174G>C | GG | 177 (0.72) | 153 (0.63) | G | 415 (0.84) | 385 (0.79) | ||||
| rs1800795 | GC | 61 (0.25) | 79 (0.33) | 0.10 | 0.034c | C | 77 (0.16) | 101 (0.21) | 0.04 | 0.40 |
| CC | 8 (0.03) | 11 (0.05) | c1.5 (1.03–2.2) | 1.4 (1.02–1.96) | ||||||
| TNFA -308G>A | GG | 202 (0.82) | 192 (0.78) | G | 443 (0.9) | 435 (0.89) | ||||
| rs1800629 | GA | 39 (0.16) | 51 (0.21) | 0.09 | A | 49 (0.1) | 53 (0.11) | 0.64 | ||
| AA | 5 (0.02) | 1 (0.01) | ||||||||
| TNFA -238G>A | GG | 199 (0.80) | 216 (0.89) | G | 445 (0.9) | 457 (0.94) | ||||
| rs361525 | GA | 47 (0.19) | 25 (0.1) | 0.019 | 0.006d | A | 49 (0.1) | 29 (0.06) | 0.02 | 0.21 |
| AA | 1 (0.01) | 2 (0.01) | d2.05 (1.2–3.45) | 1.74 (1.08–2.8) | ||||||
| IFNG +3232A>G | AA | 85 (0.35) | 61 (0.25) | A | 285 (0.58) | 265 (0.55) | ||||
| rs2069718 | AG | 115 (0.47) | 143 (0.59) | 0.026 | 0.009f, f1.6 (1.1–2.29) | G | 203 (0.42) | 221 (0.45) | 0.22 | ND |
| GG | 44 (0.18) | 39 (0.16) | 0.019e, e1.6 (1.08–2.36) | |||||||
| IFNG +874A>T | AA | 96 (0.39) | 107 (0.44) | A | 300 (0.61) | 316 (0.65) | ||||
| rs2430561 | AT | 108 (0.44) | 102 (0.42) | 0.40 | 0.40 | T | 192 (0.39) | 168 (0.35) | 0.16 | |
| TT | 42 (0.17) | 33 (0.14) |
FS score functional significance score
aRecessive model (AA vs. GG+GA); bAdditive model (GC vs. GG+CC); cRecessive model (GG vs. GC+CC); dAdditive model (GA vs. GG+AA); eRecessive model (AA vs. AG+GG); fAdditive model (AG vs. AA+GG)
Gene-gene interactions predicted using MDR
| Best combination in each order | TA | CVC |
|
|---|---|---|---|
|
| 0.562 | 10/10 | 0.100 |
|
| 0.5783 | 10/10 | 0.018 |
|
| 0.5837 | 10/10 | 0.0095 |
|
| 0.5739 | 10/10 | 0.0305 |
TA testing accuracy, CVC cross-validation consistency
aBest model
Fig. 2Distribution of cases and controls for the three-locus genotype combinations of IL6 -572, IFNG rs2430561, and IFNG rs2069718 associated with high risk and low risk for schizophrenia using MDR analysis (left bar in cell indicates cases and right bar indicates controls)
Fig. 3MDR interaction dendrogram showing interactions of pro-and anti-inflammatory cytokine genes
Fig. 4Meta-analysis of IL1A rs1800587 risk allele A versus G allele in schizophrenia patients in comparison to normal control using fixed and random model